Evaluation of Alpha 1-Antitrypsin for the Early Diagnosis of Colorectal Cancer
- 21 Downloads
Previous proteomic studies have identified alpha 1-antitrypsin (A1AT) as a potential serum biomarker for colorectal cancer (CRC). In this case-control study, we evaluated plasma A1AT concentration and activity as a biomarker for the early diagnosis of colorectal cancer in a group of 113 sporadic CRC patients. We also analyzed A1AT gene promoter methylation, and genotypes in this group of CRC patients. The plasma A1AT and CEA concentrations were measured using the nephelometric and ELISA methods, respectively. A1AT activity was determined by Trypsin Inhibitor Capacity assay. The genomic DNA from blood samples were subjected to Z and S genotype analysis using PCR-RFLP method and the gene promoter methylation in tumors and their adjacent normal tissues was determined by methylation specific-PCR assay. The plasma levels of A1AT and CEA in patients (median, 2.3 g/L and 5.96 ng/ml, respectively) were significantly higher than those in healthy controls (medians, 1.43 g/L and 2.57 ng/ml, respectively) (p = 0.0001). The plasma A1AT activity and concentrations were positively correlated with the tumor stage and well-discriminated between early and advanced stages. The A1AT activity in plasma was the most useful marker for CRC diagnosis (median 4.8 mmol/min/ml in cases vs 1.91 mmol/min/ml in controls, p = 0.0001). No deficient Z or S alleles of A1AT was observed in patients’ genotype and the gene promoter tends to be more methylated in normal mucosa than in tumor tissues. We conclude that plasma A1AT activity has better sensitivity and specificity than CEA measurement for the early detection of CRC. Promoter demethylation might play a role in increasing plasma A1AT levels in CRC patients.
KeywordsAlpha 1-antitrypsin Colorectal Cancer CEA Promoter methylation
This study was a part of the dissertation of Hajar Jaberie, submitted to Shiraz University of Medical Sciences in partial fulfillment of the requirements for the Ph. D in clinical biochemistry. This work was supported by a grant (grant number 92-6699) from the Vice Chancellor for Research, Shiraz University of Medical Sciences.
Compliance with Ethical Standards
Conflict of Interest
We declare that we have no conflict of interest.
- 15.El-Akawi ZJ, Al-Hindawi FK, Bashir NA (2008) Alpha-1 antitrypsin (alpha1-AT) plasma levels in lung, prostate and breast cancer patients. Neuro Endocrinol Lett 29:482–484Google Scholar
- 19.Trachte AL, Suthers SE, Lerner MR, Hanas JS, Jupe ER, Sienko AE, Adesina AM, Lightfoot SA, Brackett DJ, Postier RG (2002) Increased expression of alpha-1-antitrypsin, glutathione S-transferase pi and vascular endothelial growth factor in human pancreatic adenocarcinoma. Am J Surg 184:642–647 discussion 647-8CrossRefGoogle Scholar
- 21.Kwon CH, Park HJ, Choi JH, Lee JR, Kim HK, Jo HJ, Kim HS, Oh N, Song GA, Park DY (2015) Snail and serpinA1 promote tumor progression and predict prognosis in colorectal cancer. Oncotarget 6:20312–20326Google Scholar
- 23.Yang P, Cunningham JM, Halling KC, Lesnick TG, Burgart LJ, Wiegert EM, Christensen ER, Lindor NM, Katzmann JA, Thibodeau SN (2000) Higher risk of mismatch repair-deficient colorectal cancer in alpha (1)-antitrypsin deficiency carriers and cigarette smokers. Mol Genet Metab 71:639–645CrossRefGoogle Scholar
- 24.Lindor NM, Yang P, Evans I, Schowalter K, De Andrade M, Li J, Jeavons E, Peterson G, Gallinger S, Bapat B, Hopper J, Jass J, Jenkins M, Templeton A, Potter J, Newcomb PA, Lemarchand L, Grove J, Haile R, Baron J, Seminara D, Limburg P, Thibodeau SN (2010) Alpha-1-antitrypsin deficiency and smoking as risk factors for mismatch repair deficient colorectal cancer: a study from the colon cancer family registry. Mol Genet Metab 99:157–159CrossRefGoogle Scholar
- 26.Bujanda L, Sarasqueta C, Cosme A, Hijona E, Enríquez-Navascués JM, Placer C, Villarreal E, Herreros-Villanueva M, Giraldez MD, Gironella M, Balaguer F, Castells A (2013) Evaluation of alpha 1-antitrypsin and the levels of mRNA expression of matrix metalloproteinase 7, urokinase type plasminogen activator receptor and COX-2 for the diagnosis of colorectal cancer. PLoS One 8:e51810CrossRefGoogle Scholar
- 28.Yang P, Sun Z, Krowka MJ, Aubry MC, Bamlet WR, Wampfler JA, Thibodeau SN, Katzmann JA, Allen MS, Midthun DE, Marks RS, de Andrade M (2008) Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. Arch Intern Med 168:1097–1103CrossRefGoogle Scholar
- 38.Weissmann G, Zurier RB, Hoffstein S (1970) Leucocytic proteases and the immunological release of lysosomal enzymes. Am J Pathol 68:539–560Google Scholar